GLP-1 receptor agonists (GLP-1RAs) or Tirzepatide added to basal insulin than rigorously titrated basal insulin significantly ameliorates glucose control (Δ HbA<sub>1c</sub> = -1%, 95% CI -1.25; -0.74, I<sup>2</sup> 94%; Δ FPG = -14.6 mg/dL, 95% CI -21.6-; -7.6, I<sup>2</sup> 90%; chance to achieve HbA<sub>1c <</sub>7% = RR 2.62, 95% CI 2.10; 3.26, I<sup>2</sup> 89%), reduces body weight (Δ = -3.95 kg, 95% CI -5.1, -2.79, I<sup>2</sup> 96%) without increasing the risk of hypoglycemia (RR = 1.01, 95% CI 0.86; 1.18, I<sup>2</sup> 7.7%). The gene discussed is GLP1R; the disease is Hypoglycemia.